Coca-Cola Study Results Suggest Potential Benefit to Plandai Biotechnology

Coca-Cola Study Results Suggest Potential Benefit to Plandai Biotechnology 
BALTIMORE, MD -- (Marketwired) -- 08/27/13 --  Goldman Small Cap
Research, a stock market research firm focused on the small cap and
microcap sectors, notes that a research study conducted by The
Coca-Cola Company indicated that drinking polyphenol rich juice may
have benefits associated with a positive change in a major protein
that affects arterial health. These findings should be viewed as a
positive event and as corroborating third-party evidence from the
world's leading beverage producer and thus a boon to Plandai
Biotechnology (OTCQB: PLPL). Plandai plans to introduce highly
bioavailable extract products under the Company's Phytofare(TM) line
that specifically contain these polyphenols which can be used in
juices and other beverages.  
Polyphenols are derived from natural extracts and have been the
subject of extensive research due to high antioxidant activity and
demonstrated capability to eliminate free radicals, or polluted
cells. They are commonly found in green tea extracts, or green tea
gallate catechin extracts, and carotenoid botanical extracts found in
tomatoes and other 'colorful' vegetables.  
The aforementioned study was conducted in a partnership with the
University of Glasgow and Mosaiques Diagnostics, GmbH. Results
demonstrated that the levels of 27 polypeptides, which are protein or
amino acid chains in the arteries and elsewhere, increased by nearly
4 times in experimental candidates that consumed the polyphenol rich
juices over time. Therefore, the study demonstrated that drinking
green tea extract or carotenoid extract appears to improve arterial
function at the molecular level. 
Plandai's Phytofare(TM) Catechin Complex and Carotenoid Complex have
been formulated with a proprietary process that will enable the
release of more of these polyphenol compounds versus the competitors.
This product differentiation is created with superior
bioavailability, or the measurement of an amount of a compound that
is absorbed into the bloodstream. Normal extracts produce 1-10%
bioavailability, while the Phytofare(TM) extract products have
demonstrated 70% on average for bioavailability. 
Plandai is on target to begin production of the Phytofare(TM)
Catechin Complex in powder 
form, topical cream, gel tabs, and a
liquid by the end of 1Q14. The Company has partnered with several
distributors in the U.S., Europe and Africa to sell market and
distribute Plandai's Phytofare(TM) extracts in 1Q14 as well. 
Plandai's aggressive marketing campaign will reap major benefits from
the message that beverages and other products that utilize the
Phytofare(TM) products can provide superior levels of healthy
ingredients, such as the polyphenols mentioned above. This
differentiation should help the Company expand its market share and
generate strong results in 2014.  
Goldman Small Cap Research articles, reports, and updates on Plandai
as well as associated disclaimers and disclosures can be accessed or
downloaded in their entirety by visiting www.goldmanresearch.com. 
About Goldman Small Cap Research: Led by former Piper Jaffray analyst
and mutual fund manager Rob Goldman, Goldman Small Cap Research
produces sponsored and non-sponsored small cap and micro cap stock
research reports, articles, daily stock market blogs, and popular
investment newsletters. Goldman Small Cap Research is not in any way
affiliated with Goldman Sachs & Co. 
A Goldman Small Cap Research report, update, newsletter, or article
is not intended as an offering, recommendation, or a solicitation of
an offer to buy or sell the securities mentioned or discussed. Please
read all associated full disclosures, disclaimers, and analyst
background on our website before investing. Neither Goldman Small Cap
Research nor its parent is a registered investment adviser or
broker-dealer with FINRA or any other agency. To download our
research, view our disclosures, or for more information, visit
www.goldmanresearch.com. 
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai
Biotechnology, Inc. and its subsidiaries develop highly bioavailable,
phytonutrient rich extracts, which are being utilized to deliver a
new family of drugs to safely and affordably treat a multitude of
diseases and conditions. Plandai Biotechnology controls every aspect
of the process, from growing the raw materials on its farms in South
Africa, to producing the patented pending Phytofare(TM) extracts
in-house allowing the Company to guarantee the continuity of supply
as well as quality control throughout Targeted industries for the
Company's products include food and beverage, cosmeceutical,
wellness, nutraceutical, anti-aging, and pharmaceutical. For more
information, please visit http://www.plandaibiotech.com.  
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com